1. Scrip
  2. >>Business

Johnson & Johnson Gets Its Aprocitentan Money Back

Idorsia In a Fix Financially

 
• By Elizabeth Cairns

The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market. 

Idorsia building
• Source: Idorsia

Johnson & Johnson had gone quiet on the hypertension candidate aprocitentan after lacklustre data last November and now the blow has fallen: the big pharma has returned worldwide rights to the product’s originator, Idorsia Ltd., leaving the Swiss group with a longer wait for approval and little money to get there. 

The move also kiboshes the faint hope, long nurtured by the faithful,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.